Member Info for B2HS2L

I knew about the following quote, but I didn't know what I found in this link last night, so hoping it's my oversight, and others know about the basis for the above projection:
Just wanted to advise of an improvement to the above quote I found in the following link last night:

https://novacyt.annualreport2021.com/media/ftbc0qkg/novacyt-ar2021-strategic.pdf = page 25 in footer.

Strategic report
Chief Executive Officer’s Review

"Looking ahead, Novacyt’s management believes it can achieve annual revenue in excess of £100 million in five years,
whilst also delivering profit margins comparable to its peer group.
This projection is based on the successful implementation of the strategy to deliver material growth in non-covid-19 revenues."

From the RNS dated 28.04.2022 - Full year 2021 results and update on growth strategy:

"Leveraging core capabilities to become a leading, global clinical diagnostics company targeting annual revenues in excess of £100m in five years".

I've asked acting CEO James McCarthy to please insert the same statement
in it's entirety into the Full Year 2022 results, only if the statement is AS VALID NOW AS IT WAS LAST YEAR, and I should have added...now DA has moved on.

So lets hope they start with that biosensor platform that is in co-development when last we heard.

I can only see green boxes, and he's the only one filtered.
I hoped more posters would ignore him as he posts to get a response and a thrill to know he's wound up others.
I can vouch that its an easy thing to filter, as I don't miss several daily doses of piffle.
Maybe he'll find another board to haunt, (or go play on the Motorway), but not until he's getting no response here.

RNS dated 28.04.2022 - Full year 2021 results and update on growth strategy

"Leveraging core capabilities to become a leading, global clinical diagnostics company targeting annual revenues in excess of £100m in five years".

+++++++++++++++++++++

There's something we don't know about here isn't there.

+++++++++++++++++++++

"The Company intends to announce its 2022 audited full year results in the week commencing 24 April 2023 and will provide an update on the full year 2023 outlook at this time."

Let's see if the quote is repeated in the week beginning 24th April 2023.

Albeit not at all in that RNS EXMEX, just in the 'contacts' section after '- End -', well spotted.
Isn't it nice to know Novacyt PI's are so important to BoD when it comes to information delivery.

If Walbrook are happy with the way their contacts were inserted at the bottom of the document
without a change of PR agency announcement, then I don't expect information to be any easier to come by.

They have not been appointed with PI interests at heart.

Congratulations Larry.
I see this development as a sign that PR up to now had little value to BoD, but PR will now change to a large extent.
As FTI did little for us before, (possibly because they were not required to do much), then do we infer that Walbrook PR services are required, because FTI were not seen as good at their job.
Do we infer Mandy doesn't have a job any more. (Wallbrook will manage comms with non-institutional investors).
She can't be made redundant, she knows far too much.
Or do we infer that PR services are - from now on - to be valued more by the company, (ready to officially court all but II's).
It's hard to make these calls.
We didn't and don't need investment, (unless BoD M&A plans are very large indeed for such a small company).
Why would investors be interested in investing, prior to the dispute outcome, - they haven't so far.
With the dispute unresolved, nothing has changed from an investors perspective, so do we infer that the dispute might be ending before it goes to court.
Do we need PR activity for M&A, however large or small those plans might be.
"Walbrook is managing the company's ongoing communications with the financial media, research analysts and non-institutional investors, including new and existing private investors." - Specifically excluding II's, and including 'research analysts'.
If Walbrook are in the business of courting 'research analysts', is there to be an expansion of shares in issue, - these people have a habbit of wanting many shares when satisfied their investment plans are sound.
For me, internal plans are maturing, and this PR change to Woolbrook is a sign that the 2022 full year results are going to have a bit more than just last years results to convey, including major Tom's video.

I don't pretend to have any answers, but these are the issues that spring to mind from this news.
I also 100% agree that this info should have been RNS'd, - just look above, - it bloody well matters to share holders.

"This announcement has been approved for release by Alastair Smith"

Last 3 RNS's contain this text, - is he doing time or something?
Why might this be necessary?

tedious grandstanding, - that only when posters refuse to engage in any way, - is it likely to be extinguished.
I hope posters recognise now (including myself), this board has a parasite, and gains succour from others response.
How much has been worth listening to?
PI100 is remaining filtered henceforth.

cj62, - just checking you are aware of this link, pertinent to your question:

Guidance for Clinical Trial Sponsors
Establishment and Operation of Clinical Trial Data Monitoring Committees

https://www.fda.gov/media/75398/download dated 03.12.21

esecially Para
4.4.2. Early Studies

word searching 'efficacy' assisted, and gave focus to the search

Suggest you leave anyway,.
£10 / share would still leave you moaning and cluttering up this board with piffle.

(in the event of a fully successful sidetrack) -
Sell half and keep half : ¬ ) >>8>

ROFL emoji, ROFL emoji, ROFL emoji

I see that smiley face Emoji has T.W.A.T on it's forehead.

ROFL emoji, ROFL emoji, ROFL emoji

Novacyt Articles of Association (AoA) used to be available in English dated 03.06.2020, on the Novacyt website at the following link:
https://novacyt.com/wp-content/uploads/2020/09/NVT-SOC-statuts-a%CC%80-jour-2020-06-03_ENG.pdf
This link is unusable as Novacyt have replaced it.
The AoA dated 03.06.2020 in English is still available on this link:
https://www.marketscreener.com/quote/stock/NOVACYT-11681992/news/Novacyt-Articles-of-Association-31265621/

Currently the Novacyt website contains a version of the AoA dated 18.10.2021 in French only, the Novacyt Website link is:
https://novacyt.com/wp-content/uploads/2023/02/NVT-SOC-statuts-modifies-2021-10-18.pdf

I requested Mandy Cowling to make these Articles of Association available in English.
Her response to my request was
"We don’t have them in English I’m afraid, they are in French with us being a French Company."
This despite the AoA previously being available in English.

I have translated the Articles on the Novacyt website into English, and have compared them Article by Article, with those appearing on the Marketscreener website, to identify the differences between the two documents.
I noticed a difference in Articles 11 and 19. - This not an exhaustive list. Please DYOR.

In order that those shareholders needing the document in English are best served in future please repeat my request to Mandy Cowling, - and please do not accept a similar answer.

++++

Paragraph 2 of the Corporate Governance part of the Novacyt website is particularly relevant to assuring that the above situation is remedied ASAP:

Paragraph 2 - Seek to understand and meet shareholder needs and expectations

"The Company has a strong commitment to market communication, with the Directors seeking to be accountable against the stated strategic objectives of the Group. The Company maintains regular contact with Shareholders through publications such as the Annual Report and Accounts, operational updates, regular press announcements made via a regulatory information service and the Company’s website.

The Company is responsive to Shareholder telephone and email enquiries throughout the year and the Board regards the AGM as a particularly important opportunity for Shareholders and members of the Board to meet and exchange views.

The Company receives occasional feedback direct from investors, which is carefully considered by the Board, with appropriate action being taken where the Board believes it in the interests of Shareholders to do so. None of the feedback received from investors has involved non-compliance with the QCA Code."
++++

Please provide the company with plenty of feedback, else English speakers can consider ourselves to have become second class shareholders, - also known as doormats.

Axe -
"So we now know this is basically the only direction they are going in to move SNG onto another Trial" --

Well it's the only direction they are going in [that we are aware of] to move SNG onto another Trial .
I hope you don't object to the modification.

IMO the dispute is disuading predators from attempting a takeover at the present silly sp.
If that situation changes overnight, such that the dispute ends, money owed to Novacyt is paid by DHSC,
and the sp would rise accordingly.
There would be a larger risk of predators arriving, interested in a takeover without the risk of losing the dispute.
With £87M CaB, I would expect JW / JM to be trying to complete some fast M&A activity to counter the threat, whereupon sp would rise further, if they were successful.

"the share price will go through the gears in a flash".
If the above scenario should occur, that's what I'd expect to see with only 70.63 million shares in issue, and one of the first things that might happen is Board members buying stock.
All conjecture, and DHSC might win, but I believe the above is possible.

Unsure if this distributor widely known, but I recently found this:
https://midsci.com/item/ASMYGOPRO/MyGo-Pro/ St Louis USA

I'm expecting further insight from Major Tom's video Neil.

neilrich,
Did you view the link that Gizmo aluded to last night.
It may throw light on the subject.
https://www.imperial.ac.uk/news/242556/rapid-virus-testing-system-conceived-imperial/#:~:text=A%20new%20partnership%20will%20bring,costly%20productions%20to%20a%20standstill.

The UK Patent box tax regime, is a tax on profits associated with the sale of a patented product.
The UK Patent Box regime (which was not mentioned in todays budget, so I assume it remains extant), is a special low corporate tax rate used to incentivise research and development by taxing revenues from patented products differently from other revenues.
The patent box tax rate is close to 10% rather than the current UK corporation tax rate of 19% (due to rise to 25% on 01.04.2023).
So we look forward to having profits from the sale of patented products remaining close to 10% instead of the new 25% corporation taxation level, resulting in larger tax savings than we currently enjoy.

Respect to our R&D heroine Gemma Stokes, who co-created the COVID-19 (CE IVD) polymerase chain reaction (PCR) test that is the subject of the patent, the other co-creator left the company unfortunately!

https://www.eccmid.org/sponsorship-and-exhibition/sponsor-list ECCMID - European Congress of Clinical Microbiology and Infectious Diseases - Copenhagen 15-18 April 2023, Novacyt sponsoring, along with just about everyone else.

JW, as always, will have the last word.
JM owes both CFO and acting CEO positions to Wakefield.
He is at liberty to find himself another position if he should become so disposed.
Until then, if JW says jump, JM says 'how high'.
That can't be of help to many here, but it's my way of seeing the present situation, and I hope for improvements soon.